Pembrolizumab improves OS across PD-L1 subgroups
Sign Up to like & getrecommendations! Published in 2019 at "Nature Reviews Clinical Oncology"
DOI: 10.1038/s41571-019-0213-5
Abstract: in 2016, KeYNOte-024 established the superior efficacy of first-line pembrolizumab over chemotherapy for metastatic non-small-cell lung cancer (NsCLC) with a programmed cell death 1 ligand 1 (PD-L1) tumour proportion score (tPs) ≥50%. Now, overall survival… read more here.
Keywords: versus months; chemotherapy; pembrolizumab improves; across subgroups ... See more keywords